



(51) International Patent Classification:

C07D 403/12 (2006.01) A61K 31/506 (2006.01)
C07D 401/14 (2006.01) A61K 31/4178 (2006.01)
C07D 401/12 (2006.01) A61K 31/404 (2006.01)
C07D 471/04 (2006.01) A61K 31/437 (2006.01)
C07D 209/34 (2006.01) A61P 25/00 (2006.01)
A61K 31/44 (2006.01)

(21) International Application Number:

PCT/EP2013/068668

(22) International Filing Date:

10 September 2013 (10.09.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

12184249.6 13 September 2012 (13.09.2012) EP

(71) Applicant (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).

(71) Applicant (for US only): **HOFFMANN-LA ROCHE INC.** [US/US]; 340 Kingsland Street, Nutley, New Jersey 07110 (US).

(72) Inventors: **BRUNNER, Daniela**; c/o PsychoGenics Inc., 765 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **MALBERG, Jessica**; c/o PsychoGenics Inc., 765 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **SHANKAR, Bavani G.**; c/o PsychoGenics Inc., 765 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **KOLCZEWSKI, Sabine**; Minna Vortisch Strasse 12d, 79540 Loerrach (DE). **LIMBERG, Anja**; Wettsteinallee 105, CH-4058 Basel (CH). **PRINSEN, Eric**; 2, rue des Eglantines, F-68500 Guebwiller (FR).

RIEMER, Claus; Dreikoenigstrasse 31, 79102 Freiburg (DE). **STOLL, Theodor**; Rottmannsbodenstrasse 6, CH-4102 Binningen (CH).

(74) Agent: **POPPE, Regina**; Grenzacherstrasse 124, CH-4070 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS



(I)

(57) Abstract: The present invention is concerned with 2-oxo-2,3-dihydro-indoles of general formula (I) wherein (N¹) is phenyl or a heteroaryl group, selected from pyridinyl, pyrimidinyl, imidazolyl, isoxazolyl or pyrazolyl; (N²) is phenyl or pyridinyl, wherein the N atom in the pyridinyl group may be on all free positions; R¹ is hydrogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy or halogen; n is 1 or 2; if n is 2, R¹ may be the same or not; R²/R^{2'} are independently from each other lower alkyl, or form together with the carbon atom to which they are attached a C³⁻⁶-cycloalkyl ring; R³ is lower alkyl, C³⁻⁶-cycloalkyl, CH₂-C₃₋₆-cycloalkyl, C₃₋₆-cycloalkyl wherein one ring-carbon atom is replaced by -O-, (CH₂)₃-O-C₃₋₆-cycloalkyl, lower alkyl substituted by hydroxy, lower alkyl substituted by halogen, (CH₂)₃-S(O)₂-C₃₋₆-cycloalkyl or (CH₂)₂-S(O)₂-lower alkyl; R⁴ is hydrogen, halogen or lower alkyl; m is 1 or 2; if m is 2, R⁴ may be the same or not; as well as with a pharmaceutically acceptable salts thereof, with a racemic mixture, or with its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof.